denkapparat Operations GmbH Takes Position in Zoetis Inc. (NYSE:ZTS)

denkapparat Operations GmbH bought a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,288 shares of the company's stock, valued at approximately $373,000.

A number of other hedge funds also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its position in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the period. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter valued at $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis during the 4th quarter worth $58,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.6 %

Shares of ZTS stock traded down $0.98 during trading hours on Tuesday, reaching $163.67. 643,941 shares of the stock traded hands, compared to its average volume of 2,589,647. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $73.29 billion, a PE ratio of 29.92, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The business has a fifty day moving average price of $166.37 and a 200 day moving average price of $174.26.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price for the company. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $215.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.